BUSINESS

Shionogi’s Oral COVID-19 Drug Enters PI in Japan

July 27, 2021
Shionogi said on July 26 that it has launched a Japanese PI study for S-217622, an oral antiviral agent for the treatment of COVID-19. This marks the Osaka company’s first clinical trial for a therapeutic candidate specifically designed for the…

To read the full story

Related Article

BUSINESS

By Ludwig Kanzler

As reported previously, Reed Maurer passed away on August 30 due to complications from pneumonia. He was approaching his 84th birthday.Reed has been a driver of the international pharma community in Japan like nobody else. Arriving over fifty years ago…

By Takashi Ohama

Over two years after the rollout of the cost-effectiveness assessment (CEA) scheme in April 2019, discussions on its system reform are set to go into full swing at a key reimbursement policy council known as Chuikyo. Both payer and healthcare…

The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…

By Yoshinori Sagehashi

Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…